As of 2026-09-17, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (7.30) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.20 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -273.7%.
The range of the Relative Valuation is (4.70) - (9.97) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 20.7x | 12.8x |
| Forward P/E multiples | 8.4x - 17.8x | 13.2x |
| Fair Price | (4.70) - (9.97) | (7.30) |
| Upside | -212.0% - -337.4% | -273.7% |
| Date | P/E |
| 2026-09-08 | -7.57 |
| 2026-09-04 | -7.89 |
| 2026-09-03 | -7.79 |
| 2026-09-02 | -8.09 |
| 2026-09-01 | -7.95 |
| 2026-08-31 | -7.77 |
| 2026-08-28 | -7.71 |
| 2026-08-27 | -8.05 |
| 2026-08-26 | -8.11 |
| 2026-08-25 | -8.18 |
| 2026-08-24 | -8.16 |
| 2026-08-21 | -8.25 |
| 2026-08-20 | -8.27 |
| 2026-08-19 | -8.60 |
| 2026-08-18 | -8.64 |
| 2026-08-17 | -8.50 |
| 2026-08-14 | -8.55 |
| 2026-08-13 | -8.46 |
| 2026-08-12 | -8.41 |
| 2026-08-11 | -7.96 |
| 2026-08-10 | -8.09 |
| 2026-08-07 | -8.80 |
| 2026-08-06 | -9.57 |
| 2026-08-05 | -9.69 |
| 2026-08-04 | -9.74 |
| 2026-08-03 | -9.44 |
| 2026-07-31 | -9.46 |
| 2026-07-30 | -9.53 |
| 2026-07-29 | -9.16 |
| 2026-07-28 | -9.32 |
| 2026-07-27 | -9.26 |
| 2026-07-24 | -9.23 |
| 2026-07-23 | -9.26 |
| 2026-07-22 | -8.91 |
| 2026-07-21 | -9.44 |
| 2026-07-20 | -8.91 |
| 2026-07-17 | -9.34 |
| 2026-07-16 | -9.73 |
| 2026-07-15 | -11.06 |
| 2026-07-14 | -11.06 |
| 2026-07-13 | -11.49 |
| 2026-07-10 | -11.42 |
| 2026-07-09 | -11.60 |
| 2026-07-08 | -11.42 |
| 2026-07-07 | -11.42 |
| 2026-07-06 | -11.28 |
| 2026-07-02 | -11.19 |
| 2026-07-01 | -11.38 |
| 2026-06-30 | -12.33 |
| 2026-06-29 | -12.43 |